To optimize polynucleotide vaccinations for protective antitumor immunity we used a self-replicating RNA vaccine in which Semliki Forest virus replicase drives RNA expression of the lacZ gene coding for ␤-galactosidase as model tumorassociated antigen (TAA). This was compared with replicase-deficient control RNA and with lacZ DNA plasmids with respect to gene expression in vitro and in vivo and for vaccination using the mouse ear pinna as an optimal immunization site. In vitro, the highest expression was observed with self-replicating RNA. Gene expression following pinna inoculation of either non-replicating DNA plasmids or self-replicating RNA was similar, lasting for 2-3 weeks. Higher antibody responses were obtained with RNA than with DNA. ␤-Gal peptide specific CTL memory responses to lacZ DNA or RNA lasted for more than 6 weeks while respective responses induced by lacZ-transfected tumor cells lasted for only 2 weeks. To achieve a protective response against lacZ tumor cells with self-replicating RNA
Introduction
Genetic immunization with DNA vectors has become a new technology for vaccination (for review see . DNA vaccines employ genes encoding proteins of pathogens or tumors rather than using the proteins themselves. They consist of a bacterial plasmid with a strong promoter, the gene of interest and a poly-adenylation/ transcription termination sequence. The plasmid is grown in bacteria (E. coli), purified, dissolved in a saline solution and then simply injected into the host. The plasmid is taken up by host cells, transcribed into the actual mRNA and translated into protein antigens. Thus, with plasmid DNA, it is the host himself who produces the vaccine, the protein antigens. Two major properties characterize a DNA vaccine: the low level of antigen production, probably 10 3 -fold lower than in conventional vaccines, and the long-lasting expression. 4 Recently, RNA about a 100-fold lower dose of polynucleotide was sufficient in comparison to DNA. The extent of protective antitumor immunity not only depended on the gene dose used for vaccination, but also on the aggressiveness of the lacZtransfected tumor line used for challenge. In comparison to lacZ-transfected tumor cells as vaccines, polynucleotide vaccination also demonstrated superiority with regard to cross-protection. Protective antitumor immunity could be strongly increased upon co-inoculation of lacZ DNA with IL-2 DNA or IL-12 RNA. IL-2 DNA, but not IL-12 RNA, also augmented the CTL response while IL-12 RNA, but not IL-2 DNA, reduced the antibody response. These results demonstrate efficient protective antitumor immunity after intrapinna lacZ TAA polynucleotide vaccination and show additional immunomodulatory effects by co-administration of cytokine polynucleotides. Gene Therapy (2000) 7, 1137-1147.
polynucleotides have also been tested as an alternative. Cells expressing the recombinant gene and associated specialized host antigen presenting cells (APCs) process the foreign protein and present epitopes in association with MHC class I or II molecules to antigen-specific CD8 or CD4 T cells. Other parts of the protein might stimulate antigen-specific B cells. The fact that polynucleotide vaccines can induce humoral, as well as cell-mediated immune reactions against the encoded protein has opened an entirely new area of research with great clinical impact. DNA vaccination is a simpler and more economic procedure to put into practice than conventional protein vaccinations to fight infectious and other diseases in the Third World and may therefore become the poor man's version of gene therapy. 4 It may also play an increasingly significant role in protection against virus infections including HIV, autoimmune diseases, allergies and cancer. 5 We have recently compared three different vaccination sites using the bacterial lacZ gene as a model and found in the mouse that the ear pinna is a far better immunization site than muscle tissue or dermis of the abdominal skin. 6 After ear pinna DNA immunization specific humoral and cytotoxic T cell-mediated immune responses were about 10 times stronger than after immunizations at the other sites. 6 In this study we have extended this research towards optimization of protective antitumor immunity. Our systematic studies use lacZ gene as a model TAA and test protective antitumor immunity with three different lacZ transfected tumor lines differing in aggressiveness and metastatic competence. As polynucleotides we have compared non-replicating DNA plasmids and RNA with self-replicating RNA. 7, 8 Furthermore, we have coinjected cytokine DNA or RNA and tested the effect on the antibody response, on the CTL response and on protective antitumor immunity. The information obtained may be useful in future for the design of new tumor vaccines based on polynucleotides.
Results
Comparative studies with lacZ DNA and RNA Gene expression: Comparative lacZ gene expression studies were performed at the mRNA and protein level in vitro and in vivo. First we compared lacZ gene expression in vitro and in vivo using non-replicating DNA plasmids (lacZ DNA) or in vitro transcribed RNA (lacZ RNA) and self-replicating RNA (lacZ RNA + rep). For specificity control we used green fluorescent protein (GFP) DNA or RNA. Figure 1A shows slot blots of total RNA from transfected BHK-21 cells hybridized with a 32 P-labeled lacZ DNA probe. The highest specific expression levels were detected with self-replicating RNA (g, h) where the use of 1 g gave a stronger signal than that of 10 g RNA without replicase (f) or of 40 g DNA (b, c). Figure 1B shows in vivo gene expression levels 11 days after intramuscular injection of either 50 g respective DNA or 10 g respective in vitro transcribed RNA. Comparison of RNA levels showed the highest expression after injection of self-replicating lacZ RNA (g). This was stronger than those obtained from injected lacZ DNA (b, c). Figure 1C shows ␤-galactosidase protein expression in BHK-21 cells transfected with self-replicating RNA after staining with X-gal substrate in comparison to non-transfected cells (D). X-gal staining was also used to follow ␤-gal expression in the mouse ear pinna after inoculation of either lacZ DNA or self-replicating RNA (data not shown). No enzyme activity was detectable 3 h after inoculation, but 18 h later distinct stained areas were recognizable. Staining intensity increased until day 3 when ␤-gal expressing cells were concentrated at the injection site. After 6 days the areal expression seen before changed into expression patterns along distinct lines in parallel with the needle injection. After 2-3 weeks gene expression could no longer be detected in the pinna. These observations were reproducible and independent of T cell-mediated immune responses because similar observations were made in the pinna of nude (nu/nu) mice (data not shown).
Antibody responses: To test B cell-mediated immune reactions, ␤-gal-specific serum antibody titers were determined before and after immunization in solid phase ELISA against recombinant ␤-galactosidase. A monoclonal antibody served as internal control and a respective titration curve and regression analysis allowed determination of the exact antibody concentration against ␤-gal. Table 1 summarizes results from three different experiments. No specific antibodies were detected in unimmunized mice or in mice immunized with in vitro transcribed RNA coding for herpesvirus glycoprotein D (gD RNA+rep). The best polynucleotide-induced responses were obtained with lacZ RNA+rep after intrapinna immunization. Since the RNA was self-replicating, amounts as small as 3 g were found to be efficient. Following a single i.e. immunization 3 g as well as 30 g induced a titer of 15 g ␤-gal specific antibody per milliliter after 4 weeks. In comparison, the antibody titer induced by lacZ (pCMV␤) DNA was 6 g and that induced with BAG DNA 0.6 g/ml. The immune responses after pinna immunization were at least 60 times higher than after intra-muscular (i.m.) or intra-dermal (i.d.) abdominal skin immunization. The intra-pinna immune response to 5 × 10 4 live lacZ-transfected tumor cells was similar to that obtained with the pCMV␤ vector while the immune response to free ␤-galactosidase applied in complete Freund's adjuvant (CFA) was higher. The antibody titers usually were long lasting (tested up to 14 weeks) indicating the generation of a long-term B cell memory. 4 live lacZ-transfected tumor cells containing intracellular ␤-galactosidase (ESbL-lacZ) or with 100 g recombinant-free ␤-gal protein from E. coli in complete Freund's adjuvant (CFA). Serum antibody titers were determined before and after immunization with ELISA using ␤-gal protein and goat anti-mouse second antibody. Three to five mice per group were tested individually in solid-phase ELISA test for anti-␤-gal antibody content and means per group generated. A titration curve was established with anti-␤-gal mAb at 10 −5 mg/ml and titers determined via regression analysis.
Gene Therapy CTL responses: Cytotoxic CD8 T cell-mediated immune responses which may be particularly relevant for protective antitumor immunity were tested next. The kinetics of development of ␤-gal specific CTL memory responses after lacZ DNA or RNA immunization are shown in Figure 2 . Immune spleen cells from intra-pinna vaccinated mice were restimulated in vitro in mixed lymphocyte peptide cultures (MLPC) using the ␤-gal peptide TPHPARIGL which is a dominant H-2L d restricted ␤-gal CTL epitope. Five days later, the generated CTL activity was tested against 51 Cr-labeled P815-lacZ (P13.1) target cells. Other lacZ-transfected DBA/2 tumor targets such as Eb-lacZ or ESbL-lacZ could also be recognized specifically by the generated CTLs. Figure 2a shows that the CTL response generated by lacZ RNA+rep application was quite similar in terms of magnitude and kinetics to that obtained with lacZ DNA. Injection of 30 g or 3 g self-replicating lacZ RNA in the ear pinna induced a CTL response similar to that obtained with 10 g (data not shown). Mice immunized with gD RNA+rep for specificity control did not generate ␤-gal-specific CTL activity (data not shown). Specific CTL activity could no longer be detected 20 weeks after lacZ DNA inoculation. Protective antitumor immunity: Finally we determined the generation of protective antitumor immunity by polynucleotide vaccination. As shown by the results of Figure 3 the in vivo antitumor immunity obtained was dependent on the gene doses applied. When using lacZ DNA as immunogen the survival rate following Eb-lacZ tumor challenge fell from 70% when using 50 g to 60% with 10 g and 50% with 2 g or 0.4 g DNA. Only 20% of non-immmunized mice survived the tumor cell challenge. While the maximal protective effect of lacZ DNA immunization was 70%, immunization with lacZ RNA+rep revealed an optimal protection with 90% survival when using as little as 2 g RNA. Even 0.4 g RNA resulted in 70% survival while the use of a higher dose (10 g) was less effective (50% survival).
The extent of protective antitumor immunity was not only dependent on the gene dose used for vaccination but also on the immunobiology and aggressiveness of the lacZ-transfected tumor line used for challenge as Figure 4 illustrates. Groups of mice that were identically vaccinated with 50 g lacZ DNA in the pinna developed either a strong protective antitumor immunity when challenged with P815-lacZ mastocytoma cells 9 (a), or a partial protec- tive immunity when challenged with Eb-lacZ lymphoma cells 10 (b) or they developed only a shift in the survival curve with no complete protection when challenged with ESbL-lacZ lymphoma cells. 11 ESbL-lacZ cells used at a dose of only 1 × 10 5 were shown before to be highly aggressive and metastatic, 12 while the P815-lacZ mastocytoma cells used at a dose of 4 × 10 6 were nonmetastatic. No stronger protection against the aggressive ESbL-lacZ cells could be obtained when using lacZ self-replicating RNA instead of lacZ DNA for vaccination. Nevertheless, a highly significant (P = 0.0007) and specific protective effect was seen after challenge with ESbL-lacZ cells when testing for local tumor growth ( Figure 5 ). Preimmunization with 50 g lacZ DNA (II) or 10 g selfreplicating lacZ RNA (IV) prevented tumor outgrowth within 12 days in the majority of animals, while this was not the case when using GFP DNA (III), non-replicating lacZ RNA (V), or self-replicating GFP RNA (VI). Although the extent of protection was different depending on the aggressiveness of the tumor cells used for challenge, all three tumor lines were affected by the vaccination with lacZ DNA or self-replicating lacZ RNA. This is not necessarily so when using lacZ-transfected tumor cells for primary immunization as shown by the results in Table 2 . The three tumor lines already intro- duced in Figure 4 together with nontransfected parental tumor lines as control were used for primary immunization in the ear pinna. Nine days later, when the immune response was established, different groups of mice were challenged s.c. with one of the three lacZtransfected tumor lines in such a way as to check for cross-protection mediated via lacZ-induced immune responses. To circumvent an influence of immune responses to endogenous TAAs no challenge was perforGene Therapy med with the identical tumor line as used for immunization. These experiments revealed complete cross protection between certain tumor lines (such as P815-lacZ and Eb-lacZ) but not between others (P815-lacZ and ESbL-lacZ). There was partial cross-protection between Eb-lacZ and ESbL-lacZ cells. The reasons why immunization with ESbL-lacZ which induced specific anti-␤-gal CTL activity, did not induce cross-protection to P815-lacZ cells which could so well be protected by immunization with lacZ DNA or lacZ RNA+rep has not yet been elucidated. The results, however, demonstrate the superiority of polynucleotide vaccination in comparison to conventional cancer vaccines.
ESbL-lacZ cells. Tumor diameter was measured 12 days later. Each dot represents the tumor size of an individual mouse while the numbers in brackets indicate the number of animals (more than one) showing the same tumor size value. The black horizontal line represents the mean value of tumor diameter in each group. Group II and IV were significantly (P Ͻ 0.01) different from group I (Fisher's exact test, Bonferroni corrected). Similar results were obtained in a second experiment in which identically immunized mice were challenged with P815-lacZ tumor cells (not shown).
Immune response modulation by co-injection of lacZ polynucleotide vectors with cytokine polynucleotide vectors Various cytokine DNA or RNA vectors were used to test their effect on the immune response upon co-injection together with lacZ as TAA. To test whether a particular immune response induced by lacZ polynucleotide vaccination could be up-or down-modulated in the presence of co-expressed biologically active cytokine, the lacZ DNA was mixed with cytokine DNA or RNA in the same syringe and injected together. Some of the results are shown in Figure 6 . Co-inoculation of self-replicating IL-12 RNA+rep caused a clear-cut down-regulation of the anti-␤-gal antibody response (a). The antigen-specific CTL response was affected positively by IL-2 DNA (b). Control gD RNA+rep which does not code for a cytokine had an augmenting effect on the cell-mediated immune response (b) and a down-regulatory effect on the humoral response (a). The results show that coinjection of lacZ DNA with other polynucleotide vectors can down-modulate the humoral immune response (also observed with IL-7 DNA) and augment the cell-mediated immune response (also seen with IL-7 DNA).
We next tested the effect of immune modulation on protective anti-tumor immunity. Figure 6c illustrates results obtained from mice pre-immunized with lacZ DNA and either cytokine RNA or cytokine DNA constructs and challenged 3-4 weeks later s.c. with Eb-lacZ tumor cells. The best protection (100%) was observed by co-administration of self-replicating RNA coding for IL-12 and DNA coding for IL-2. No such effects were observed with GM-CSF RNA+rep or DNA.
We have demonstrated in these TAA immunization model studies that protective antitumor immunity can be induced very well in the ear pinna by lacZ polynucleotide immunization in the form of DNA or RNA and that humoral immune responses, CTL responses and protective immunity can be modulated by co-application of polynucleotides encoding defined cytokines.
Discussion
This study extends previous work on polynucleotide vaccination using the mouse ear pinna as an optimal site for immunization. 6 New in this study are the use of selfreplicating RNA 7, 8 in addition to DNA vectors, the measurement of protective antitumor immunity in addition to humoral and T cell-mediated immune responses and the use of cytokine vectors to modulate the immune responses against ␤-galactosidase as model TAA. To test for protective antitumor immunity, preimmunized mice were challenged with three different lacZ-transfected tumor lines differing in aggressiveness.
The rationale for polynucleotide immunizations derives from the following facts: (1) this approach elicits both humoral and cell-mediated immune responses without using adjuvants; (2) intracellular synthesis of antigen favors MHC class I peptide display which is considered pivotal to the generation of CTL; (3) gene expression in vivo can be long-lasting; and (4) large quantities of purified polynucleotides can be constructed, prepared and standardized with relative ease compared with attenuating a pathogen or with protein purification techniques. DNA and RNA reagents can be used as preventive vaccines or as therapeutic vaccines for treatment of a variety of diseases. Genetic vaccines have been tested in a number of different species against more than 25 pathogens (for reviews see Ref. 13 ) and also against cancer (for reviews see Refs 3 and 14) .
The data obtained with the lacZ gene show a superiority of a self-replicating RNA as compared with nonreplicating RNA or DNA plasmids: 2 g of RNA+rep were sufficient to induce protective antitumor immunity in 70% (above control) of animals challenged with the lacZ transfected lymphoma Eb while the same amount of DNA caused protection in only 30% (above control) of similarly challenged animals (Figure 3) . 0.4 g RNA+rep still induced protective immunity in 50% (above control) of challenged animals. To achieve a similar protective antitumor immunity with DNA plasmids we had to use 10-50 g, ie about 100 times the amount needed with self-replicating RNA.
Figure 6 Immune modulation of lacZ DNA induced immune responses by co-inoculation of cytokine nucleotides. Three experiments are presented. One (a) shows the humoral immune responses. Two other experiments (I and II) show CTL responses (b) and protective anti-tumor immunity (c). Mice were immunized with 50 g lacZ DNA alone or together with 50 g of cytokine DNA (I) or 3 g self-replicating cytokine RNA (II). (a) Sera taken 2 weeks later were diluted as indicated and tested by ELISA for anti ␤-gal antibodies. (b) Three weeks after immunization, immune spleen cells were restimulated in vitro with ␤-gal peptide for 5 days. The specific CTL activity was determined in a 4 h 51 Cr release assay using P815-lacZ (P13.1) as specific target cells and the effector to target cell ratios (E:T) indicated. (c) Pre-immunized (B-I) and nonimmunized control mice (A) were challenged either 4 weeks (exp I) or 3 weeks (exp II) after immunization, s.c. with 2 × 10 6 Eb-lacZ cells. Values indicate percentage overall survival after 100 days.
Vaccines that use RNA may be safer than DNA 15 vaccines because RNA is directly translated into proteins and does not integrate into the host cell DNA. Disadvantages of RNA in comparison to DNA could be lower stability and shorter expression time. RNA-liposome complexes 16 or gene-gun transfer 17 have been employed to overcome these obstacles. In this study we used a selfreplicating positive strand RNA derived from a DNA plasmid in which the lacZ gene is positioned behind the replicase gene of Semliki Forest virus. Directly after RNA uptake into the cytoplasm, the recombinant RNA drives its own replication and capping and leads to massive production of heterologous protein while competing out the host cell protein synthesis. 7, 8 The use of SFV based selfreplicating RNA obviates many problems that are encountered in the conventional 'nuclear' DNA expression systems, such as mRNA splicing, limitations in transcription factors, problems with capping efficiency and mRNA transport. The cytopathic effects appear rather late during infection so that there is an extensive time window from about 4 h up to at least 48 h after infection during which a high expression level is combined with negligible morphological cellular changes. 7 Recombinant Sindbis virus 18 or flavivirus 19 RNA has also been used to express antigen, but this approach is problematic due to high-level production of vector structural proteins and for biosafety reasons. With regard to the SFV replicon-based RNA, vector proteins other than the viral RNA polymerase are not expressed, and a high level of biosafety is achieved. Owing to the self-replicating nature of the recombinant RNA molecule, problems with dosage can be overcome. We show here by application in the pinna that doses smaller than 1 g RNA are sufficient to induce immunity. The extremely high expression levels seen in the SFV system combined with the optimal injection site of the pinna may explain the efficiency of generating cellular and humoral immune responses, as well as protective antitumor immunity.
Following injection of polynucleotides in solution with a thin needle between the dorsal and ventral sites of the pinna, we found that the kinetics of gene expression were similar when using nonreplicating DNA or selfreplicating RNA. Expression lasted for 2-3 weeks with a maximum between 1 and 10 days. The change of gene epxression pattern in the pinna by time could indicate polynucleotide cell to cell transport. Termination of expression seemed to be independent of T cell-mediated immune responses because similar observations were made in the pinna of nude (nu/nu) mice. Termination could be related to down-regulation of promoter activity (in case of DNA plasmids) and/or to cell death and/or to disappearance of the cells from the site of inoculation. Recently it was shown that self-replicating RNA 20 and plasmid DNA replicons 21 mediate homogeneous antigen production in all transfected cells associated with the apoptotic death of the transfected host cells. The apoptotic bodies would be taken up by dendritic cells which would take care that the engulfed antigen be optimally processed and presented for induction of T cell-mediated immunity. 22 The disappearance of expressed antigen from the pinna after polynucleotide immunization could be advantageous to prevent the generation of chronic inflammatory and autoimmune reactivity. We showed before that a second polynucleotide immunization, if required, can further boost the immune response. 6 Our previous studies on pinna resection at different times after DNA application as well as the staining of antigen expressing cells at the site of application and also in the draining lymph node 6 suggested that migrating cells, in particular dendritic cells (DCs) are involved in the immune response as professional antigen-presenting cells (APCs). Others came to similar conclusions. [23] [24] [25] [26] In a recent study, a DNA vaccine coding for nonsecreted fifth component of complement (C5) protein was applied by scarification of the mouse ear skin with a 25-gauge needle. Although the majority of DNA was taken up by keratinocytes it could be shown that a strong, long-lived CD4 T cell response to the non-secreted protein was initiated in the draining lymph nodes by a small number of DC that expressed the antigen. Although DNA vaccination resulted in direct transfection of only a very small proportion of DC it led to general activation of all DC found in the draining lymph nodes thus providing optimal conditions for effective T cell activation. 27 In our comparative analysis we studied the humoral and the T cell-mediated immune response to the model TAA ␤-galactosidase as well as the protective antitumor immunity. The humoral immune response after pinna immunization was at least 60 times higher than after i.m. or i.d. abdominal skin immunization ( Table 1 ). The best responses were obtained with lacZ RNA+rep where 3 g were found to be efficient following a single immunization and induced a titer of 15 g ␤-gal-specific protein per milliliter after 4 weeks. The response was specific since a control self-replicating gD RNA plasmid coding for herpesvirus glycoprotein D did not induce any anti-␤-gal antibodies. The humoral immune response to 50 g of the lacZ DNA vector was about half as strong and similar to the response induced by intra-pinna inoculation of a subtumorigenic dose of 5 × 10 4 live lacZ-transfected tumor cells. Co-inoculation of IL-12 self-replicating RNA, IL-7 DNA or GM-CSF DNA caused a clear-cut downregulation of the humoral immune response, in particular when tested during the rising phase of the response (Figure 6a) .
The induction of antigen-specific T cell responses was tested at the level of ␤-gal peptide (TPHPARIGL)-specific CTL memory responses. 6 These were revealed by stimulating immune spleen cells from intra-pinna vaccinated mice for 5 days in MLPC and then testing CTL activity against 51 Cr-labeled lacZ-transfected lymphoma or mastocytoma tumor target cells. Application of 3 g selfreplicating lacZ RNA in the pinna induced a similar CTL response as 50 g lacZ DNA. Co-administration of IL-2 or IL-7 DNA as well as non-coding control gD-RNA had an augmenting effect on the CTL response (Figure 6b ). While the effects of the cytokine DNA vectors may be due to the effect of the expressed cytokine, 28 the effect seen with gD-RNA indicates a nonspecific adjuvant-like activation effect on the immune system. It was reported from other systems that bacterial DNA might alert the immune system to foreign invading species due to nonmethylated dinucleotides such as CpG 29, 30 or unusual conformations such as Z-DNA or base composition. Figure 2 shows the superiority of intra-pinna polynucleotide immunizations (a) in comparison to other more conventional forms of vaccination (b) with regard to duration of an antigen-specific CTL memory response. While immunization with 100 g recombinant ␤-gal protein did not induce CTL responses at all, possibly because of an inefficient uptake into an MHC I presentation pathway, [31] [32] [33] immunization with 5 × 10 4 lacZ expressing tumor cells caused a CTL memory response of only short (less than 2 weeks) duration. In contrast, CTL memory responses after polynucleotide vaccination lasted for more than 6 weeks although the amount of lacZ RNA expressed in the tissue was much less than in the tumor cells. While it has been reported that cytotoxic T cell memory can exist without antigen, 34 it was recently shown that memory CD8 cells were the progeny of cyto-toxic effector cells and retained antigen-specific CTL activity 10 weeks after adoptive transfer to antigen-free recipient mice. 35 Our long-term CTL memory response after polynucleotide vaccination would therefore suggest that this approach caused an effective differentiation of naive CTL precursors into CTL effectors which then gave rise to the CTL memory cells.
Recently it was reported that in order to stimulate strong immunity, naked DNA or viral vectors must be expressed in professional APCs or be delivered in a manner that will promote exogenous antigen presentation. 36, 37 Other important aspects seem to be (1) antigen expression levels; (2) kinetics of antigen processing and presentation by professional APCs; 23 and (3) kinetics of immune response induction in draining lymph nodes. The external ear pinna as a special extension from the skin is rich in APCs, which after appropriate activation, migrate to one major pinna draining lymph node, the superficialis cervicalis. In abdominal skin, in contrast, drainage occurs into several lymph nodes, some axillary and others inguinal. The route of DNA application thus decides on the anatomical microenvironment for immune response induction. Immune response induction in the pinna draining lymph node appears to be very fast. We showed that within 24 h after immunization radiation sensitivity of ESb tumor resistance in the pinna changes to radiation resistance. 38 Furthermore CD4 helper T cells 39 as well as CD8 T cells 38 were required for ESb tumor resistance in the pinna. Recently we found that ESb tumor inoculation into the pinna (where the cells do not grow) induces a Th1-type cytokine response while s.c. inoculation (where the tumor cells grow) induces a Th2-type cytokine response. 40 Thirty minutes after ESbLlacZ cell inoculation into the pinna ␤-gal-expressing cells were already detectable in the draining node 41 suggesting dissemination (active or passive) of tumor cells from the site of inoculation. If some of these were to die by apoptosis, DCs would be able to acquire antigen from them to induce class I restricted CTLs. 33 Also, DCs could become conditioned to function as a temporal bridge 42 between a CD4 T helper and a T killer cell.
The extent of protective antitumor immunity, as tested in a tumor prevention assay, depended on the immunobiology and aggressiveness of the lacZ-transfected tumor line used for challenge. While there was only partial protection against the high metastatic line ESbL-lacZ, 11 complete protection was obtained when using the low metastatic P815-lacZ mastocytoma. 9 This difference was observed in spite of the fact that a 40-fold higher tumor cell number was used with the latter tumor line where complete protection was seen. Nevertheless, all three transfected tumor lines could be affected by prophylactic immunization with polynucleotide vaccines (Figure 4 ). This was not necessarily so when using lacZ-transfected tumor cells for primary immunization ( Table 2 ). The reasons why immunization with ESbL-lacZ cells, which induced specific CTL activity and antibodies, did not induce cross-protection to P815-lacZ is presently not clear. Multiple lineages of tumors expressing a common TAA, were previously found to not necessarily crossprotect. 43 Co-administration of cytokine DNA coding for IL-2 had an augmenting effect on the ␤-gal specific CTL response (Figure 6b ) and on protective antitumor immunity against Eb-lacZ lymphoma cells (Figure 6c ). Some protection augmenting effect was also seen by coadministration of self-replicating gD RNA which also augmented CTL activity. A very good protection was also observed by co-administration of self-replicating RNA coding for IL-12, although this did not have an effect on the CTL response. In tumor treatment test systems, IL-12 has been reported to have a strong anti-metastatic effect in mice 44 and mouse rIL-12 given as an adjuvant following DNA vaccination had a profound effect on the growth of established lung metastases. 45 IL-12 RNA codes for a gene product required at low concentrations to help the immune system fight cancer. Such gene therapy could possibly also be applied systemically, 13 since systemic gene expression was reported following intravenous DNA delivery into adult mice. 46 Alternatively, coinoculation with plasmids expressing cytokines could be used for manipulating the immune response to a plasmid-encoded antigen. 47 Immune response manipulation via plasmid DNA vaccination was shown to be able to activate Th2 immunity thereby preventing autoimmune encephalitis. 48 Conversely, a Th2-type response to HIV-1 induced by epidermal gene gun immunization could be driven towards Th1 by co-administration of plasmids encoding IL-2, IL-7 or IL-12. 49 In this study we used lacZ not only as a gene tag for tumor cells, 50 but as a model TAA. With regard to polynucleotide-mediated immunization therapy of human cancer, transforming TAA such as HER-2/neu may be approached with self-replicative RNA constructs. The efficacy of this approach will soon be examined in clinical trials in patients with cancer.
14 The vast majority of cloned human TAA represent nonmutated self antigens present in some normal adult tissue, such as CEA in the gastrointestinal (GI) tract, HER-2/neu in breast and GI tract, MART-1 in skin and retina, MAGE-1 in testes, tyrosinase and gp100 in skin and retina and MUC-1 in breast, pancreas and GI tract.
14 Thus, issues of tolerance and potential autoimmune toxicity will be important considerations for most human tumor relevant antigens. The use of polynucleotides coding for unique TAA arising from point mutations, eg of ras 51 or p53 52 oncogenes or from incompletely spliced mRNA 53 may reduce such risks. A DNA immunization-mediated induction of a protective antigen-specific antitumor immune response has already been reported for a mutated human p53 epitope 54 and for human papillomavirus type 16E7. 55 Observations on feasibility and efficacy of such strategies in humans will hopefully soon be available. The results of this study demonstrate that there are plenty of ways to mix and match DNA vectors with RNA to design novel strategies for the use in gene therapy and immunotherapy of cancer.
Materials and methods

DNA and RNA constructs
In the retrovirus-based vector BAG (7.2 kb) (a gift from Dr C Cepko, Department of Genetics, Harvard Medical School, Boston, MA, USA), the expression of the lacZ gene is driven by the Moloney murine leukemia virus (MMLV) LTR promoter. This vector contains also a neomycin resistance gene (neo R ) under the control of a SV40 promoter. In the pCMV␤ vector named lacZ DNA, from Clontech (Heidelberg, Germany, Genbank Accession No. U02451), lacZ expression is regulated by the CMV immediate-early gene promoter. The pCMVSPORT-␤gal vector (named lacZ DNA sp) which contains CMV immediate-early promoter/enhancer was purchased from Life Technologies (Karlsruhe, Germany). The pEGFP-C1 DNA (named GFP DNA) which expresses green fluorescen protein (GFP) also under the control of CMV immediate-early promoter was purchased from Clontech. Green fluorescent protein (GFP) was cut out from this vector and subcloned into the JMPpSFV1 vector 8 (kindly provided by Dr J Meanger) using the BssHII and ApaI restriction sites. The transcribed RNA is called GFP RNA+rep. The IL-2 expression vector was kindly provided by Dr P Kulmburg (Department of Hematology/Oncology, University of Freiburg Medical Center, Freiburg, Germany) who cloned the 0.45 kb IL-2 gene into the pRC/CMV vector (Invitrogen, Leek, The Netherlands) which contains neo R . The IL-7 expression vector which contains an MMLV LTR promoter was provided by Immunex (Seattle, WA, USA). The GM-CSF expression vector (7.5 kb) was kindly provided by Dr D Pardoll (Johns Hopkins University, Baltimore, MD, USA). In this pcDNAIneo vector (Invitrogen), the 0.5 kb PCR product of the murine GM-CSF gene is regulated via a CMV promotor. Plasmids were grown in Escherichia coli (OHS␣) and purified using the Endo Free Maxi Plasmid Kit from Qiagen (Hilden, Germany). The DNA used for injections was freshly diluted and adjusted to 1 g/l in 1 × PBS final concentration.
The pSFV3-lacZ vector was purchased from Life Technologies (Karlsruhe, Germany). The in vitro transcribed RNAs of the following genes: lacZ, GFP, IL-12, GM-CSF and gD (coding for herpesvirus glycoprotein D) were derived from recombinant DNA plasmids as templates containing the replicon of Semliki Forest virus (pSFV) or a control plasmid (pCMVSPORT-␤-gal, named lacZ RNA) containing no replicon. These RNAs were in vitro transcribed and capped using SP6 RNA polymerase (Life Technologies).
Slot blots
Total RNA from transfected cells or from injected muscle tissue was prepared using RNA clean method (AGS/Hybaid, Heidelberg, Germany) according to the manufacturer's instructions. Following shock freezing, muscle tissue was homogenized using an Ultra Turrax T25 (IKA, Staufen, Germany) homogenizer. Five micrograms of total RNA from transfected BHK-21 cells and 20 g of total RNA from injected muscle tissue were subjected on to slot blot. Total RNA was denatured, blotted on to nylon membranes (Gene Screen, Biotech Systems, Boston, MA, USA), cross-linked with UV and hybridized for 24 h at 42°C with a 32 P-labeled lacZ DNA probe according to standard molecular biology protocols. Membranes were then exposed at −70°C to X-ray film (Kodak, XOMatic, Rochester, NY, USA).
Mice
Pathogen-free female DBA/2 mice were purchased from IFFA Credo (Belgium) and used at 6-12 weeks of age.
Cells and transfections BHK-21 baby hamster kidney cells were cultured in G-MEM medium (Glasgow minimum essential medium) supplemented with 5% FCS, 10% tryptose phosphate Gene Therapy broth, 10 mm Hepes (pH 7.3), 2 mm glutamine, 100 U/ml penicillin and 10 g/ml streptomycin. The cells were maintained at 37°C with 5% CO 2 . BHK-21 cells were transfected with 40 g of the DNA and 1 or 10 g of the RNA constructs by electroporation. Electroporation was performed at room temperature by one pulse at 200 V and 960 F capacitance for the DNA transfections and two pulses at 850 V and 25 F capacitance for the RNA transfections using a Gene Pulser (BioRad, Mü nchen, Germany). Forty-eight hours later an aliquot of the cells was stained with X-gal 10 for estimating the transfection efficiency and expression of lacZ, and the rest of the cells were used for total RNA preparation for slot blot.
Tumor lines
Eb-lacZ, a low metastatic lacZ-transfected lymphoma 10 and ESbL-lacZ, its highly metastatic lacZ-transfected variant, 11, 12 P815, a mastocytoma, and its lacZ transfected variant P13.1, 9 were all cultivated in RPMI-1640 medium, as described earlier. 6 
Peptide
The synthetic nonamer TPHPARIGL represents the naturally processed H-2L d restricted epitope of ␤-galactosidase spanning amino acids 876-884. 9 It was synthesized by R Pipkorn (DKFZ, Heidelberg, Germany).
Immunizations with DNA, RNA, protein and tumor cells DNA vectors or in vitro transcribed RNA, dissolved in 50 l PBS, were injected into the ear pinna (i.e.) of anesthetized animals using 32 G needles. Anesthesia was carried out by intraperitoneal injection of Rompun-Ketanest-PBS (1:1:3). Alternatively, for testing expression, the DNA and RNA constructs dissolved in 50 l PBS were injected into the tibialis anterior muscle of anesthetized DBA/2 mice using 27 G needles. Eleven days later total muscle RNA was prepared and 20 g of total RNA were hybridized by slot blot to a 32 P-labeled lacZ DNA probe. Recombinant free ␤-gal protein (Sigma, Deisenhofen, Germany) emulsified in complete Freund's adjuvant (1:1) was used for i.p. immunization. For immunization with tumor cells a subtumorigenic dose of 5 × 10 4 ESbL-lacZ cells in 50 l PBS was injected i.e.
Tumor challenge
Tumor growth experiments in pre-vaccinated or control animals were performed by s.c. inoculation in the neck of 0.1 ml PBS containing the indicated numbers of washed tumor cells from cell culture.
ELISA
Blood samples were obtained from the tail vein of mice every second week. Sera were prepared and stored at −20°C until they were analyzed for anti-␤-gal antibodies in ELISA as described. 6 Effector cells generated in mixed lymphocyte-peptide cultures (MLPC) Animals were immunized with 50 g lacZ DNA i.m., i.d. or i.e. Nine to 28 days later, 2 × 10 7 of their immune spleen cells were restimulated in vitro for 5 days in RPMI medium containing 10% FCS and 0.5 g/ml TPHPA-RIGL peptide. Alternatively, 5 × 10 4 live ESbL-lacZ cells in 50 l PBS were inoculated i.e. and 9 days later splenocytes were restimulated in vitro as above.
Gene Therapy
51
Cr release assay The effector cells generated in MLPC were tested for their cytotoxic activity in a standard 4 h 51 Cr release assay at different effector:target ratios against 5 × 10 3 51
Cr labeled P13.1 and P815 cells, respectively, as described. 6 The amount of 51 Cr released was measured in a gamma counter and the percentage of lysis was calculated from the formula: ((experimental c.p.m. − spontaneous c.p.m.)/(maximum c.p.m. − spontaneous c.p.m.)) × 100.
X-gal staining Ear pinnae were removed from the animals and stained immediately in X-gal solution at 37°C for 3-16 h as described. 6 
